SG Americas Securities LLC Sells 4,250 Shares of Humana Inc. (NYSE:HUM)

SG Americas Securities LLC decreased its holdings in shares of Humana Inc. (NYSE:HUMFree Report) by 60.0% in the 4th quarter, Holdings Channel reports. The fund owned 2,828 shares of the insurance provider’s stock after selling 4,250 shares during the period. SG Americas Securities LLC’s holdings in Humana were worth $717,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. International Assets Investment Management LLC boosted its holdings in shares of Humana by 261,025.1% during the 3rd quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock worth $2,340,660,000 after buying an additional 738,701 shares in the last quarter. FMR LLC increased its holdings in Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after acquiring an additional 643,291 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Humana by 55.6% in the 3rd quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock worth $190,145,000 after purchasing an additional 214,535 shares during the period. Pzena Investment Management LLC boosted its stake in Humana by 8.1% in the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after purchasing an additional 187,903 shares during the period. Finally, Worldquant Millennium Advisors LLC bought a new stake in shares of Humana during the 3rd quarter valued at about $50,102,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Down 2.9 %

Humana stock opened at $294.18 on Thursday. The firm has a fifty day moving average price of $275.44 and a two-hundred day moving average price of $303.14. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market cap of $35.42 billion, a price-to-earnings ratio of 26.06, a P/E/G ratio of 2.15 and a beta of 0.55.

Humana (NYSE:HUMGet Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The firm had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. As a group, analysts forecast that Humana Inc. will post 16.11 earnings per share for the current year.

Insider Activity at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.32% of the stock is currently owned by company insiders.

Analyst Ratings Changes

HUM has been the subject of several research reports. Oppenheimer cut their target price on Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, October 3rd. Jefferies Financial Group downgraded Humana from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $519.00 to $253.00 in a report on Monday, October 7th. Royal Bank of Canada cut their target price on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. TD Cowen increased their price objective on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Finally, Morgan Stanley raised their target price on Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $297.68.

Get Our Latest Report on Humana

About Humana

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.